Tonix Clinical Site
Welcome,         Profile    Billing    Logout  
 5 Trials 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Melamed, Isaac R
NCT04705831: Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Recruiting
4
40
US
Ruconest
IMMUNOe Research Centers
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
01/22
01/22
KIDCARES10, NCT04944979 / 2020-001496-32: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients

Recruiting
3
30
Europe, US, RoW
Kedrion IVIG 10%
Kedrion S.p.A., Pharmaceutical company, KEDRION S.p.A, Kedrion S.p.A
Primary Immunodeficiency Disease
04/26
10/26
LUNA3, NCT04562766 / 2020-002063-60: Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

Active, not recruiting
3
194
Europe, Canada, Japan, US, RoW
Rilzabrutinib, PRN1008, Placebo, PRN1008 Placebo
Principia Biopharma, a Sanofi Company, Principia Biopharma, Inc.
Immune Thrombocytopenia
06/25
11/26
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Completed
2
91
US
AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo
Avalo Therapeutics, Inc.
Non-Eosinophilic Asthma
05/23
05/23
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Completed
2
63
US
TNX-102 SL, Placebo SL Tablet
Tonix Pharmaceuticals, Inc.
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
07/23
07/23
NCT04589403: 1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

Recruiting
1
15
US
OPT101, 15-mer peptide
Op-T LLC
Healthy
06/24
06/24
INSPIRE, NCT04288921: Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

Recruiting
N/A
2000
US
Swab
LumiraDx UK Limited
Influenza, Human, Respiratory Syncytial Virus Infections
09/23
09/23
Collins, Maureen
NCT04705831: Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection

Recruiting
4
40
US
Ruconest
IMMUNOe Research Centers
Post-Viral Fatigue Syndrome, Post-Viral Disorder (Disorder), Covid19
01/22
01/22
KP415P01, NCT05685732: An Efficacy and Safety Study w/ Azstarys® in Children With ADHD

Completed
4
246
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH), placebo
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac
Attention Deficit/Hyperactivity Disorder
05/24
05/24
KP415P02, NCT05721235: A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Active, not recruiting
4
123
US
Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH)
Corium, Inc., Premier Research Group plc, Prometrika, LLC, Almac, Worldwide Clinical Trials
Attention Deficit/Hyperactivity Disorder
07/25
07/25
KIDCARES10, NCT04944979 / 2020-001496-32: Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients

Recruiting
3
30
Europe, US, RoW
Kedrion IVIG 10%
Kedrion S.p.A., Pharmaceutical company, KEDRION S.p.A, Kedrion S.p.A
Primary Immunodeficiency Disease
04/26
10/26
PRIOH-1, NCT03073967 / 2020-004940-27: Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

Recruiting
3
153
Europe, Canada, US, RoW
Pritelivir, Investigator's choice, Foscarnet or Cidofovir or Imiquimod
AiCuris Anti-infective Cures AG, Medpace, Inc.
HSV Infection
07/25
11/25
PREVAIL, NCT05472090: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Completed
2
63
US
TNX-102 SL, Placebo SL Tablet
Tonix Pharmaceuticals, Inc.
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
07/23
07/23
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Active, not recruiting
2
208
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
09/23
03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting
2
196
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Chronic Inducible Urticaria
06/24
09/25

Download Options